NCT00954304View on ClinicalTrials.gov

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2009

Conditions
Healthy
Interventions
DRUG

HM30181AK 1mg

HM30181AK 1mg tablet

DRUG

HM30181AK 5mg

HM30181AK 5mg tablet

DRUG

HM30181AK 15mg

HM30181AK 15mg tablet

DRUG

HM30181AK 60mg

HM30181AK 60mg tablet

DRUG

Loperamide 2mg

Loperamide 2mg capsule

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT00954304 - Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet | Biotech Hunter | Biotech Hunter